© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
September 23, 2021
An expert reviews the ongoing ARIEL4 phase III trial and explains what the future of ovarian cancer treatment looks like.
Lyndsay Willmott, MD, explains the tolerability of PARP inhibitors for ovarian cancer and how to discuss dose reductions with patients.
A key opinion leader shares data from a phase III, ARIEL3, clinical trial on rucaparib maintenance treatment for ovarian cancer.
Dr. Lyndsay Willmott discusses the front-line therapy options for ovarian cancer and the factors considered in choosing maintenance therapies.
An oncologist explains the importance of molecular testing in ovarian cancer and the implications of testing on treatment selection.
Lyndsay Willmott, MD, presents the case of a 57-year-old woman with ovarian cancer.